Keyphrases
Primary Antibody Deficiency
100%
COVID-19
83%
Inducer
66%
Matrix Metalloproteases
66%
Extracellular Matrix
66%
Replacement Product
53%
Immunoglobulin Replacement
53%
Antibody Deficiency
47%
Neutralizing Activity
46%
Combination Therapy
40%
Omicron Variant
38%
Antibody Response
38%
Booster Vaccination
33%
Dual Combination
33%
IgG1
33%
Death Receptor 5
33%
Memory B-cell Response
33%
Simian Virus 40 (SV40)
33%
Damage Signaling
33%
Signaling Kinases
33%
Antagonistic Effect
33%
Pancreatic Cancer
33%
Pancreatic Adenocarcinoma
33%
MRE11-RAD50-NBS1 Complex
33%
Chemotherapy
33%
MRNA Vaccine
33%
Ataxia Telangiectasia mutated
33%
Hypovascular
33%
SARS-CoV-2 Infection
33%
TRA-8
29%
Immunoglobulin
22%
MIA PaCa-2
21%
T Antigen
20%
Anti-spike
20%
Gemcitabine
20%
Tumor Growth
17%
Tumor
17%
B Cell Response
14%
Primary Vaccination
14%
Lapachone
13%
Receptor-binding Domain
13%
Titer
13%
Antireceptor
13%
CUL7
12%
Viral DNA Replication
12%
Protective Behavior
12%
Healthy Donors
12%
Immunoglobulin Prophylaxis
11%
Cytotoxicity
11%
Immune Deficiency
11%
Immunology and Microbiology
Humoral Immune Deficiency
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Intravenous Immunoglobulin
55%
Omicron Coronavirus Variant
41%
Antibody Response
38%
Proteasome
33%
Immunoglobulin G1
33%
Simian Virus 40
33%
Memory B Cell
33%
Ataxia Telangiectasia
33%
Death Receptor
33%
Extracellular Matrix
33%
DNA Virus
33%
DNA Synthesis
33%
Virus
22%
Spike
20%
COVID-19
18%
Viral Replication
16%
DNA Damage
16%
Receptor Binding
16%
Protein Degradation
16%
Cuniculidae
14%
B Cell
14%
Titer
11%
Cytotoxicity
11%
Immune Response
9%
T Cell
9%
Antibody Titer
9%
Steady State
8%
Virus Mutant
8%
Wild Type
8%
Cell Extract
8%
Ubiquitins
8%
Immunodeficiency
7%
Cell Line
7%
Neutralizing Antibody
5%
Fc Receptor
5%
Humoral Immunity
5%
Hepatitis Delta Virus
5%
Medicine and Dentistry
Metalloproteinase
66%
Extracellular Matrix
66%
Combination Therapy
46%
Neoplasm
37%
Memory B Cell
33%
Death Receptor 5
33%
Humoral Immune Deficiency
33%
Severe Acute Respiratory Syndrome Coronavirus 2
33%
Immunoglobulin G1
33%
Pancreas Adenocarcinoma
33%
Pancreatic Cancer
33%
Gemcitabine
20%
Tumor Progression
17%
B Cell
14%
T-Cell Response
14%
Cytotoxicity
11%
In Vitro
11%
Positron Emission Tomography-Computed Tomography
10%
Dynamic Contrast-Enhanced MRI
10%
Tumor Model
10%
Immune Response
9%
COVID-19 Vaccine
9%
Messenger RNA
9%
Technetium-99
7%
Cell Line
7%
Therapy Effect
6%
Pancreas Tumor
6%
Monotherapy
6%
Fluorine-18
6%
CD147 Antigen
6%
Arm
6%
Vascularity
6%
